Bioline RX Ltd Sponsored ADR (BLRX) has released an update.
BioLineRx Ltd has announced the presentation of new economic model data for their drug APHEXDA®, aimed at improving stem cell mobilization in multiple myeloma patients, at the ISPOR 2024 conference. The data suggests potential cost and healthcare resource utilization benefits when APHEXDA® is used with filgrastim compared to current standard apheresis practices. This advancement could reduce the number of apheresis sessions required, alleviating patient burden and enhancing apheresis center efficiency.
For further insights into BLRX stock, check out TipRanks’ Stock Analysis page.
